Slide 1: Transforming health through the human microbiome
rsonal use only Transforming health through the human microbiome Q3 FY24 Results ASX: MAP 23 April 2024 Authorised for release by the Board of Directors
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 3: Microba is a Medical Diagnostic and Clinical Stage Therapeutics Company
Microba is a Medical Diagnostic and Clinical Stage Therapeutics Company unlocking the Human Microbiome rsonal use only • Microba was founded in late 2017 on world-leading metagenomic microbial genomic and microbiome analysis technology • A clear vision for routine use of diagnostic metagenomic testi
Slide 4: Microba's evolution into a medical diagnostic and clinical stage therapeutics company
Microba’s evolution into a medical diagnostic and clinical stage therapeutics company rsonal use only Agreement with Strategic investment Insert Europe’s largest & agreement with Insight non-diagnostic medical diagnostics Laboratory receives global medical MetaXplore MetaPanel test launched directly
Slide 5: Q3 Results: Financial & Business Highlights
rsonal use only Q3 Results Financial & Business Highlights 5
Slide 6: Q3 Financial Highlights
Q3 Financial Highlights Strong Revenue Growth in Australia, First Full Quarter of Revenue from Invivo Clinical in the United Kingdom rsonal use only $4.00m in revenue for Q3 | +82% QoQ | +297% YoY Q3 Revenue growth YoY* Q3 Revenue growth QoQ* (A$m) (A$m) • $4.03m in Q3 FY24 cash 297% 82% receipts, u
Slide 7: Recent Milestones & Highlights
Recent Milestones & Highlights TESTING THERAPEUTICS rsonal use only 1) Strong growth for Gastrointestinal Disorder Test, 1) Inflammatory Bowel Disease Program MetaXplore, in Australia. – Progressing to Phase II ready. - 1,100 tests sold during Q3 FY24, - Activities were conducted to prepare 28% sale
Slide 8: Microbiome Services
rsonal use only Microbiome Services Driving global revenues and data growth 8
Slide 9: Q3 Revenue Highlight - Australia MetaXplore growth
Q3 Revenue Highlight - Australia MetaXplore growth rsonal use only 28% 1,167% • Strategic clinician education and sales efforts in Australia over the last 6 months are materialising in Growth QoQ Growth YoY an acceleration of growth in test sales 1,100 2,854 • Multiple growth campaigns executed incl
Slide 10: Q3 Revenue Highlight - Australia MetaPanel launched
Q3 Revenue Highlight - Australia MetaPanel launched rsonal use only • First doctor referrals and sales achieved across New South Launch Event First Test Wales, Victoria, Queensland, South Australia, Western Completed Sales Australia and Tasmania NSW • Launch events held across New South Wales, V
Slide 11: Q3 Revenue Highlight - United Kingdom, Invivo first full quarter
Q3 Revenue Highlight – United Kingdom, Invivo first full QTR rsonal use only 1,668 4,947 • First full quarter of sales and revenue were delivered, generating $2.23m in sales Q3 Tests Sold Tests Sold FYTD • Financial and corporate integration is now complete • Focussed on sales growth within 5,900 ex
Slide 12: Next generation gastrointestinal diagnostic tests
Next generation gastrointestinal diagnostic tests Gastrointestinal pathogen test Gastrointestinal disorder test rsonal use only One sample. 7 functional GI markers. 175 targets. >28k microbiome markers. Expertly curated clinical Expertly curated clinical recommendations for recommendations for targe
Slide 13: Patient pathway - Advancing the standard of care for GI symptoms
Patient pathway — Advancing the standard of care for GI symptoms rsonal use only Is it a pathogen Is this a functional Patient presents with causing these Is there risk of GI disorder or mental GI symptoms. IBD or CRC? health disorder? symptoms? IBD risk test faecal If negative IBS Diagnosis by excl
Slide 14: Patient pathway - Advancing the standard of care for GI symptoms
Patient pathway — Advancing the standard of care for GI symptoms Functional microbiome Colonoscopy for formal Targeted antibiotic and or GI disorder diagnosis IBD or CRC diagnosis DGBI treatment /or with personalised New Microba and treatment treatment plan care pathway rsonal use only If positive I
Slide 15: Microbiome Therapeutics
rsonal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies
Slide 16: Advanced AI/ML Approach for Next Generation Precision Live Biotherapeutics
| Microba is Pioneering an Advanced AI/ML Approach for the Development of Next Generation Precision Live Biotherapeutics World’s most advanced bioinformatic pipeline for metagenomic microbiome analysis rsonal use only Large human dataset with deep health metadata powering AI/ML* discovery Pipeline o
Slide 17: Microba is a leader in Precision Microbiome Therapeutics
Microba is a leader in Precision Microbiome Therapeutics Microba Partners Precision microbiome analysis platform delivering rsonal use only unparalleled accuracy, coverage & depth. Data driven discovery platform utilising one of the world’s most advanced & highly curated microbiome datasets. N
Slide 18: Recent Program Highlights
| Recent Program Highlights Inflammatory Bowel Disease Program rsonal use only Progressing to Phase 2 ready. • Phase 1 study completed successfully demonstrating excellent safety profile and first indication of potential engraftment • Phase 2 clinical study design completed, Phase 2 CMC and regulato
Slide 19: Human data driven insights
Human data driven insights rsonal use only Microbiome OA NAFLD RA Databank IBS Asthma Eczema Health Data PS IBD T2D Neurological Disorders and Mental Health Biome Data GORD Lupus Obesity IO CVD Precision Microbiome Therapeutics 19
Slide 20: Advanced AI/ML Approach for Next Generation Precision Live Biotherapeutics
| Microba is Pioneering an Advanced AI/ML Approach for the Development of Next Generation Precision Live Biotherapeutics Target Prediction Disease Relevant Activity rsonal use only Disease Donor Prevalence Isolation Human Data Driven Precision AI & Machine Microbiome Health Data Learning Therapeutic
Slide 21: Therapeutic Pipeline
Therapeutic Pipeline rsonal use only Development Core Program Discovery R&D Preclinical Phase 1 Phase 2 Phase 3 Partners Undisclosed (LBP) IBD (Ulcerative Colitis) MAP 315 (LBP) Undisclosed Immuno-oncology (LBP) Undisclosed Autoimmune (LBP) • Live Biotherapeutic Product (LBP) 21
Slide 22: Inflammatory Bowel Disease Program: MAP 315
Inflammatory Bowel Disease Program : MAP 315 New data supporting MOA Phase II trial readiness Additional supporting data including new Study start timing currently being determined - rsonal use only insights into how MAP 315 promotes Adaptive Patient Study, N = 140 to 200 examining mucosal healing (
Slide 23: Oncology Program
Oncology Program Expanded Clinical Dataset for Lead Discovery OMICO & PrOSPeCT study rsonal use only • ~1,000 metagenomics samples from 8 studies across multiple cancer types • Microba is a collaborating partner in have been complied to discover gut microbiome signatures associated with the landmark
Slide 24: Autoimmune Program
Autoimmune Program Stage 2 Screening • Data generated showing impact on Observing broad and potent immunomodulatory activity rsonal use only fibrosis, gut barrier integrity, nuclear receptor biology, GPCRs and ER stress • Next assays to include broad gene expression and cytokine profiling. • On trac
Slide 25: Advancing allergy treatment partnership with IFF
Advancing allergy treatment partnership with multi-national probiotics leader IFF Stage 2 signed to complete isolation and activity rsonal use only assessment • Strain isolation activities underway and on track • Strong collaboration built between both teams NYSE IFF | Market cap $19.6B* | HQ New Yo
Slide 26: 3rd Generation of Microbiome Therapeutics
Microba is developing the 3rd Generation of Microbiome Therapeutics using a human data driven approach 1 First Generation 2 Second Generation 3 Next Generation rsonal use only Faecal Doner Derived & FMT Bacterial Consortia Single Strain & Small Molecule FDA approval Nov 30 2022 Vedanta Biosciences F
Slide 27: Outlook
Outlook MICROBA Ajuo asn yeuosia
Slide 28: Upcoming Company Milestones
Upcoming Company Milestones 2023 2024 2024 JUL - DEC JAN - MAR APR - JUN rsonal use only Testing Testing Testing New country expansion Invivo Clinical integration Stage 2 US commercialisation strategy Testing Testing Testing First Sonic partners operational Sonic MetaPanel national launch Me
Slide 29: Therapeutic program milestone tracking
| Therapeutic program milestone tracking Inflammatory Bowel Disease Immuno-Oncology Program Autoimmune Diseases rsonal use only PHASE I COMPLETE PRECLINICAL STAGE 2 SCREENING Recently Completed Recently Completed Recently Completed Phase I HREC approval Leads discovered Program commenced cGM
Slide 30: Contact
rsonal use only Dr Luke Reid CONTACT Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Chairman Princess Alexandra Hospital pasquale.rombola@microba.com Woolloongabba QLD Australia
Slide 31: Two core business segments driven by a world leading technology
Two core business segments driven by a world leading technology World leading microbiome rsonal use only analysis technology Testing Business Proprietary databank Therapeutics Business Next generation gastrointestinal diagnostics Advanced AI and biostatistics powering a diagnostics and Precision mic